Wells Fargo & Company Reaffirms “Overweight” Rating for Integer (NYSE:ITGR)

Integer (NYSE:ITGR)‘s stock had its “overweight” rating reiterated by analysts at Wells Fargo & Company in a report released on Tuesday, Marketbeat reports. They currently have a $160.00 price objective on the medical equipment provider’s stock. Wells Fargo & Company‘s price objective would suggest a potential upside of 13.90% from the company’s previous close.

A number of other research firms have also recently issued reports on ITGR. Piper Sandler restated an “overweight” rating and set a $140.00 price target (up from $125.00) on shares of Integer in a report on Friday, October 25th. KeyCorp increased their price target on Integer from $139.00 to $144.00 and gave the stock an “overweight” rating in a report on Tuesday, October 15th. Truist Financial cut their price target on Integer from $150.00 to $147.00 and set a “buy” rating on the stock in a report on Friday, October 25th. Benchmark increased their price target on Integer from $130.00 to $140.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Finally, Bank of America increased their price target on Integer from $135.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday, October 1st. One analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, Integer currently has a consensus rating of “Moderate Buy” and an average target price of $142.00.

Integer Stock Down 0.5 %

Shares of NYSE ITGR opened at $140.47 on Tuesday. The company has a current ratio of 3.28, a quick ratio of 2.09 and a debt-to-equity ratio of 0.67. The company has a market cap of $4.71 billion, a price-to-earnings ratio of 43.35, a PEG ratio of 1.99 and a beta of 1.12. Integer has a 12 month low of $86.42 and a 12 month high of $142.76. The stock has a 50-day moving average price of $132.12 and a two-hundred day moving average price of $124.89.

Integer (NYSE:ITGR) last released its quarterly earnings data on Thursday, October 24th. The medical equipment provider reported $1.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.36 by $0.07. The company had revenue of $431.42 million during the quarter, compared to the consensus estimate of $440.59 million. Integer had a return on equity of 11.63% and a net margin of 6.70%. The firm’s revenue was up 8.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.27 earnings per share. As a group, analysts forecast that Integer will post 5.33 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Integer

Large investors have recently bought and sold shares of the stock. Blue Trust Inc. lifted its stake in Integer by 460.4% during the 2nd quarter. Blue Trust Inc. now owns 5,643 shares of the medical equipment provider’s stock valued at $658,000 after acquiring an additional 4,636 shares in the last quarter. Loomis Sayles & Co. L P increased its position in shares of Integer by 3.0% during the 3rd quarter. Loomis Sayles & Co. L P now owns 538,027 shares of the medical equipment provider’s stock valued at $69,943,000 after purchasing an additional 15,446 shares during the last quarter. Earnest Partners LLC increased its position in shares of Integer by 3.2% during the 2nd quarter. Earnest Partners LLC now owns 1,208,319 shares of the medical equipment provider’s stock valued at $139,911,000 after purchasing an additional 37,340 shares during the last quarter. Great Lakes Advisors LLC increased its position in shares of Integer by 56.7% during the 2nd quarter. Great Lakes Advisors LLC now owns 45,218 shares of the medical equipment provider’s stock valued at $5,236,000 after purchasing an additional 16,355 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new stake in shares of Integer during the 3rd quarter valued at $651,000. 99.29% of the stock is currently owned by institutional investors.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.